PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
R&D reduction while AXSM shows 14.98% growth. Joel Greenblatt would examine competitive risk.
-6.73%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
55.79%
Other expenses change of 55.79% while AXSM maintains costs. Bruce Berkowitz would investigate efficiency.
-5.86%
Operating expenses reduction while AXSM shows 7.85% growth. Joel Greenblatt would examine advantage.
-5.86%
Total costs reduction while AXSM shows 7.85% growth. Joel Greenblatt would examine advantage.
-72.88%
Both companies reducing interest expense. Martin Whitman would check industry trends.
55.79%
D&A growth less than half of AXSM's 184.54%. David Dodd would verify if efficiency is sustainable.
-143.43%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
5.86%
Operating income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-101.24%
Other expenses reduction while AXSM shows 78.46% growth. Joel Greenblatt would examine advantage.
-142.73%
Pre-tax income decline while AXSM shows 0.50% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-72.88%
Both companies reducing tax expense. Martin Whitman would check patterns.
-142.73%
Net income decline while AXSM shows 0.50% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-120.58%
EPS decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-120.58%
Diluted EPS decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
10.21%
Share count change of 10.21% while AXSM is stable. Bruce Berkowitz would verify approach.
10.21%
Diluted share change of 10.21% while AXSM is stable. Bruce Berkowitz would verify approach.